Literature DB >> 24046331

Targeted precise quantification of 12 human recombinant uridine-diphosphate glucuronosyl transferase 1A and 2B isoforms using nano-ultra-high-performance liquid chromatography/tandem mass spectrometry with selected reaction monitoring.

John K Fallon1, Hendrik Neubert, Theunis C Goosen, Philip C Smith.   

Abstract

Quantification methods employing stable isotope-labeled peptide standards and liquid chromatography-tandem mass spectrometry are increasingly being used to measure enzyme amounts in biologic samples. Isoform concentrations, combined with catalytic information, can be used in absorption, distribution, metabolism, and excretion studies to improve accuracy of in vitro/in vivo predictions. We quantified isoforms of uridine-diphosphate glucuronosyltransferase (UGT) 1A and 2B in 12 commercially available recombinant UGTs (recUGTs) (n = 49 samples) using nano-ultra-high-performance liquid chromatography-tandem mass spectrometry with selected reaction monitoring). Samples were trypsin-digested and analyzed using our previously published method. Two MRMs were collected per peptide and averaged. Where available, at least two peptides were measured per UGT isoform. The assay could detect UGTs in all recombinant preparations: recUGTs 1A1, 1A3, 1A4, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B15, and 2B17, with limit of detection below 1.0 pmol/mg protein for all isoforms. The assay had excellent linearity in the range observed (2-15.5 pmol/mg, after dilution). Examples of concentrations determined were 1465, 537, 538, 944, 865, 698, 604, 791, 382, 1149, 307, and 740 pmol/mg protein for the respective isoforms. There was a 6.9-fold difference between the maximum and minimum recUGT concentrations. The range of concentrations determined indicates that catalytic rates per mg total protein in vitro will not accurately reflect isoform inherent specific activity for a particular drug candidate. This is the first report of a targeted precise quantification of commercially available recUGTs. The assay has potential for use in comparing UGT amounts with catalytic activity determined using probe substrates, thus allowing representation of catalysis as per pmol of UGT isoform.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24046331      PMCID: PMC3834135          DOI: 10.1124/dmd.113.053801

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  13 in total

Review 1.  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.

Authors:  R H Tukey; C P Strassburg
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 2.  Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases.

Authors:  Michael H Court
Journal:  Methods Enzymol       Date:  2005       Impact factor: 1.600

3.  Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring.

Authors:  John K Fallon; Hendrik Neubert; Ruth Hyland; Theunis C Goosen; Philip C Smith
Journal:  J Proteome Res       Date:  2013-09-26       Impact factor: 4.466

4.  Quantification of human uridine-diphosphate glucuronosyl transferase 1A isoforms in liver, intestine, and kidney using nanobore liquid chromatography-tandem mass spectrometry.

Authors:  David E Harbourt; John K Fallon; Shinya Ito; Takashi Baba; Joseph K Ritter; Gary L Glish; Philip C Smith
Journal:  Anal Chem       Date:  2011-12-05       Impact factor: 6.986

5.  Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences.

Authors:  J K Ritter; F K Kessler; M T Thompson; A D Grove; D J Auyeung; R A Fisher
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

6.  Immunochemical identification of UGT isoforms in human small bowel and in caco-2 cell monolayers.

Authors:  M F Paine; M B Fisher
Journal:  Biochem Biophys Res Commun       Date:  2000-07-14       Impact factor: 3.575

7.  UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics.

Authors:  Zhiming Wen; Melanie N Tallman; Shazia Y Ali; Philip C Smith
Journal:  Drug Metab Dispos       Date:  2006-12-06       Impact factor: 3.922

8.  Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities.

Authors:  Sumio Ohtsuki; Olaf Schaefer; Hirotaka Kawakami; Tae Inoue; Stephanie Liehner; Asami Saito; Naoki Ishiguro; Wataru Kishimoto; Eva Ludwig-Schwellinger; Thomas Ebner; Tetsuya Terasaki
Journal:  Drug Metab Dispos       Date:  2011-10-12       Impact factor: 3.922

9.  Absolute quantification of human uridine-diphosphate glucuronosyl transferase (UGT) enzyme isoforms 1A1 and 1A6 by tandem LC-MS.

Authors:  John K Fallon; David E Harbourt; Saber H Maleki; Fay K Kessler; Joseph K Ritter; Philip C Smith
Journal:  Drug Metab Lett       Date:  2008-08

10.  Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase.

Authors:  J Seppen; P J Bosma; B G Goldhoorn; C T Bakker; J R Chowdhury; N R Chowdhury; P L Jansen; R P Oude Elferink
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

View more
  20 in total

1.  Quantification of Four Efflux Drug Transporters in Liver and Kidney Across Species Using Targeted Quantitative Proteomics by Isotope Dilution NanoLC-MS/MS.

Authors:  John K Fallon; Philip C Smith; Cindy Q Xia; Mi-Sook Kim
Journal:  Pharm Res       Date:  2016-06-29       Impact factor: 4.200

2.  Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential.

Authors:  Guillaume Margaillan; Michèle Rouleau; Kathrin Klein; John K Fallon; Patrick Caron; Lyne Villeneuve; Philip C Smith; Ulrich M Zanger; Chantal Guillemette
Journal:  Drug Metab Dispos       Date:  2015-06-15       Impact factor: 3.922

Review 3.  Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.

Authors:  Upendra A Argikar; Philip M Potter; J Matthew Hutzler; Punit H Marathe
Journal:  AAPS J       Date:  2016-08-05       Impact factor: 4.009

Review 4.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Amin Rostami-Hodjegan; Aleksandra Galetin
Journal:  AAPS J       Date:  2016-06-30       Impact factor: 4.009

5.  Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction.

Authors:  Brandon T Gufford; Gang Chen; Ana G Vergara; Philip Lazarus; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2015-06-12       Impact factor: 3.922

Review 6.  Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation.

Authors:  Daniel Scotcher; Christopher Jones; Maria Posada; Aleksandra Galetin; Amin Rostami-Hodjegan
Journal:  AAPS J       Date:  2016-08-09       Impact factor: 4.009

7.  Identification of diet-derived constituents as potent inhibitors of intestinal glucuronidation.

Authors:  Brandon T Gufford; Gang Chen; Philip Lazarus; Tyler N Graf; Nicholas H Oberlies; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2014-07-09       Impact factor: 3.922

8.  Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance.

Authors:  Kathleen M Knights; Shane M Spencer; John K Fallon; Nuy Chau; Philip C Smith; John O Miners
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

9.  Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo.

Authors:  Brandon T Gufford; Jessica Bo Li Lu; Ingrid F Metzger; David R Jones; Zeruesenay Desta
Journal:  Drug Metab Dispos       Date:  2016-01-22       Impact factor: 3.922

10.  Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9.

Authors:  Kohei Yamamoto; Marina Mukai; Kenjiro Nagaoka; Keiko Hayashi; Hiroyuki Hichiya; Kenji Okada; Mikio Murata; Masato Shigeyama; Shizuo Narimatsu; Nobumitsu Hanioka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-01-28       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.